Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger)

Bullboard Posts

Comment by Jefferam1on Mar 20, 2018 6:13pm

94 Views

Post# 27749720

RE:RE:RE:Sell in the AM - Misleading results

I second that;
What he said!

SpaceBeer wrote: Yeah...what he said! :P

StrikingMoose wrote: You're so dumb. The control group had 1000mg active naproxen in two 550mg tabs. Atb346 only has ~165mg naproxen covalently bound to TZB. So it's 1/6th the naproxen. Oh boy quick cancel all the trades it's a scam! Lol. That's why this is such a big deal. The naproxen isn't even metabolized as normal naproxen does because the covalent bond doesn't break before the molecule is metabolized. It's metabolized into a new substance that suppresses cox activity without raising plasma naproxen levels and allowing the ulcerative injury to happen.